Michael Geffner - Jan 26, 2024 Form 4 Insider Report for Immunovant, Inc. (IMVT)

Signature
/s/ Eva Renee Barnett, attorney-in-fact for Michael Geffner
Stock symbol
IMVT
Transactions as of
Jan 26, 2024
Transactions value $
-$383,012
Form type
4
Date filed
1/29/2024, 04:11 PM
Previous filing
Jan 16, 2024
Next filing
Apr 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMVT Common Stock Sale -$377K -9.95K -9.95% $37.91 90.1K Jan 26, 2024 Direct F1, F2
transaction IMVT Common Stock Sale -$5.88K -153 -0.17% $38.45 89.9K Jan 26, 2024 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On January 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 3 filed on January 16, 2024, of which 25,000 of these RSUs vested on January 17, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.
F2 The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $37.44 - $38.41 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.
F3 The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.45 - $38.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.